Apexium Financial’s Vivos Therapeutics VVOS Stock Holding History

Apexium Financial’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,627	Closed	-$7.81K	–	274
2023 Q3	$7.81K	Hold	1,627	–	–	﹤0.01%	212
2023 Q2	$20.7K	Hold	1,627	–	–	﹤0.01%	219
2023 Q1	$13.9K	Hold	1,627	–	–	﹤0.01%	210
2022 Q4	$16.3K	Hold	1,627	–	–	﹤0.01%	204
2022 Q3	$26K	Buy	+1,627	New	+$49.6K	﹤0.01%	194

Other funds holding VVOS

SWIG

Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Apexium Financial's VVOS Position: Q4 2023 in Review

Apexium Financial sold out of Vivos Therapeutics (VVOS) in Q4 2023, closing a stake of 1,627 shares — an estimated $7.81K sold.

Apexium Financial first reported a position in VVOS in Q3 2022 and held it in 5 quarters. The position peaked at $26K in Q3 2022. 18 funds tracked by Wall St. Rank hold VVOS as of Q4 2023.

Apexium Financial reported no remaining Vivos Therapeutics position as of Q4 2023 after selling out during the quarter.
Apexium Financial sold 1,627 Vivos Therapeutics shares in Q4 2023, an estimated $7.81K.
Apexium Financial first reported a position in Vivos Therapeutics in Q3 2022 and held it in 5 quarters.
Apexium Financial's Vivos Therapeutics position peaked at $26K in Q3 2022.
18 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2023.

Based on Apexium Financial's 13F filing for Q4 2023, filed 8 Feb 2024.